NOX 0.00% 7.2¢ noxopharm limited

Lu-PSMA data, page-4

  1. 438 Posts.
    lightbulb Created with Sketch. 211
    NO!! because - as you well know- you can’t take the results of one arm in one study (n> 800), compare with another study (lupin n= 56) especially as there is much more imprecision in small sample (remind us again what the median survival confidence levels are in lupin?) , and go hey we’re X% better. It’s dumb, it’s unscientific and would make any credible statistician cringe. Sure it’s useful knowing what the other studies are showing and setting a context, but this knee jerk need to manufacture statistics for a headline is pure BS.
    I know you’re emotionally connected to Nox and self appointed spokesperson for them on this forum (or maybe a Nox employee??) but stop trying to make up data or conclusions that aren’t valid or claim somethings “incontrovertible” when it clearly isn’t - please - coz it just gets exposed!!

    btw: any update on the Covid trial cytokine analyses?

    a bientot
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.